FDAsafety guidance66% confidence
FDA AP — ESTRADIOL (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Mylan; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA075182. Sponsor: MYLAN TECHNOLOGIES. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ESTRADIOL.
Supporting Context
- Therapeutic area
- Pain Management · Opioid
- Sub-indication
- Pain
Related signal: FDA Grants AP Status for Mylan's Fentanyl Supplement